Liverpool City Region - Biomanufacturing Capital of Europe

The Northwest is part of the UK's top three biomedical cluster and well as a member of the 'European Super League' of biotech clusters.

It is estimated more people work in producing pharmaceuticals in Liverpool than in any other European city.

90 companies in the Liverpool City Region contribute more than £1billion to the region's economy, including multinational names such as Novartis, Eli Lilly, MedImmune, Unilever R&D, Bristol Myers Squibb and Numico.

A further 2,000 employees are working in biomedical and clinical research in universities, hospitals and research institutes. We are also home to the world leading Liverpool School of Tropical Medicine and the National Biomanufacturing Centre.

Key Industry Features and Benefits

• A significant cluster of life sciences research and clinical activity includes biomedical biotechnology, infectious diseases, bio/pharmaceutical manufacturing and diagnostic and medical technology.
• Novartis, MedImmune and Eli Lilly are three of the global brands with bases in South Liverpool. Eli Lilly´s manufacturing facility is the largest bulk-biotechnology facility in the UK, while MedImmune produces the FluMist flu vaccine. Liverpool's Novartis facility produces the swine flu vaccine, amongst others.
• The National Biomanufacturing Centre, Europe's leading biopharmaceutical design centre. With the capability to develop and manufacture a wide variety of novel biopharmaceutical medicines for early phase clinical trials, the NBC works with biotech companies or academic groups to bring new medicines from the research laboratory into the clinic.
• The Liverpool City Region boasts the UK's highest output of medical-related graduates. Its universities are at the forefront of research and innovation in life sciences.
• The world's first medical institution dedicated to the teaching and study of tropical diseases, the Liverpool School of Tropical Medicine remains at the forefront of globally significant research programmes. It is at the forefront of research into the control of malaria, tuberculosis and HIV/AIDS and continues to further develop its capabilities following funding from the Bill and Melinda Gates Foundation. Centre for Tropical and Infectious Diseases (CTID) has considerably expanded facilities and capacity to research and develop new drugs, vaccines and pesticides to combat some of the world's most devastating diseases
• Liverpool Biomedical Research Centre is the UK's leading specialist research centre. It is allowing scientists to develop pioneering tests and treatments for a range of conditions such as Clostridium difficile, HIV, tuberculosis (TB), cystic fibrosis and drug safety.
• The National Zoonosis Centre is the world's first interdisciplinary centre devoted to the study of animal-borne diseases such as avian flu, BSE and SARS, established at the University of Liverpool.
• The Cockcroft Institute is the international Centre for Accelerator Science and Technology (AST). It is part of Daresbury Laboratory, which is utilising its resources in computational science and structural analysis for life sciences applications, particularly understanding protein structure and function.
• The Liverpool City Region is home to twelve National Health Service (NHS) Trusts with research capabilities and large patient registers in critical disease areas, a key consideration when conducting phase 2 and 3 trials.
• Daresbury Science & Innovation Campus (SIC) has been identified by the government as a key driver for UK's science-based economy and aims to become the pre-eminent location in the North of England for pioneering 'big' science.
• Alder Hey is the largest children's hospital in Western Europe. It is the birthplace of modern paediatric anaesthesia; neonatal surgery and children's cardiac surgery were pioneered here.
• Liverpool Science Park provides a home for developing science and knowledge based companies by offering a accommodation and business support. Following the success of its innovation centre (ic1), Liverpool Science Park's second state-of-the art facility ic2 opened its doors in June 2009. Situated in the striking environs of Liverpool's metropolitan cathedral, ic2 provides 40,000 sq ft of highly specified flexible office and laboratory compatible accommodation
• Liverpool is home to the MerseyBIO Incubator facility which provides dedicated training courses.
  
  

Existing investors include:
Novartis, Eli Lilly, MedImmune, Powder Systems, PI Biosciences, Bristol Myers Squibb, Contract Chemicals, Mast Diagnostics, Micap, Unilever, Manesty, Eden Biopharm, Protherics, Tessenderlo, Terumo, Sequence Biotechnologies, Provexis.

A dedicated agency BioNow supports life sciences businesses through the provision of specialist advice.
For more information about this sector contact Neil Bradley, Corporate Sales Manager on 07736002253
A downloadable brochure Investing in Liverpool and Merseyside Life Sciences provides further information for companies looking to invest in the Life Sciences sector. Hard copies are also available.